Osteoporosis (OP) is a metabolic bone disease affecting nearly 200 million individuals globally. Morinda Officinalis How (MOH) has long been used as a traditional herbal medicine for the treatment of bone fractures and joint diseases in China. However, it still remains unclear how the compounds in MOH work synergistically for treating OP. In this study, we used prednisolone (PNSL)-induced zebrafish OP model to screen the antiosteoporosis components in MOH. A network pharmacology approach was further proposed to explore the underlying mechanism of MOH on OP. The PNSL-induced zebrafish model validated that two anthraquinones, one iridoid glycoside, and two saccharides exerted antiosteoporotic effect. We constructed the components-targets network, and obtained the enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. A total of 26 candidate compounds of MOH and 257 related targets could probably treat OP through regulating osteoclast differentiation and MAPK signaling pathway. Our work developed a strategy to screen the antiosteoporosis components and explore the underlying mechanism of MOH for treating OP at a network pharmacology level.© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.
January 17, 2020
Gender differences in respiratory health outcomes among farming cohorts around the globe: findings from the AGRICOH consortium.
March 18, 2020
Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
May 12, 2020